Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
40 / 100
Risk factors
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2026
- Supply of Nilotinib (ATC L01EA03) under a non-exclusive framework agreement.
- Excludes Nilotinib dispersed in apple sauce unless patented.
Show full summary
Non-exclusive drug discount agreement for Nilotinib (ATC L01EA03) via an Open-House model. Contract ends 31.07.2026. Open to all qualified pharmaceutical entrepreneurs meeting German statutory requirements. No guaranteed volumes or exclusivity. Estimated value not published. Submission possible periodically until final deadline.
Risks
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered medicinal products.
- Legal seat within Germany, EU, or EEA (§9 Abs. 2 AMG).
Eligibility
- No exclusion grounds under §§123, 124 GWB (submission of self-declaration).
Requirements may be incomplete.
Buyer
Name
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib
Single lot covering Nilotinib (excluding apple sauce dispersion unless patented). Open House model – any qualified pharmaceutical entrepreneur may join by submitting required documents. No negotiation or exclusivity.
Location
Duration
Category
Deadline
Award details
Selection criteria
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 349678-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
40 / 100
Risk factors
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications